HCC CONNECT Experts Knowledge Share - Appropriate selection of patients for combination immunotherapy in HCC: the now and the next.

Tuesday, May 11th 2021
JST (+1 DAY)

About This Meeting

A virtual Experts Knowledge share on the topic of “Appropriate selection of patients for combination immunotherapy in HCC: the now and the next” Chaired by Prof. Peter Galle, MD, PhD (Germany) and co-chaired by Prof. Sammy Saab, MD (USA) and Prof. Amit Singal, M.D., M.S (USA)

The educational objectives for the meeting are:

  • To provide insights into the combination therapy for unresectable or advanced HCC patients, covering both approved therapies and those that are in clinical development.
  • To define the HCC patient population who should benefit most from each available treatment option based on efficacy and safety profile.
  • To provide guidance on treatment sequencing

Meeting Materials

To view meeting materials, you need to be registered for the meeting.


Peter Galle, MD, PhD
Mainz, Germany
Amit Singal, M.D., M.S
Dallas, USA
Sammy Saab, MD
Los Angeles, USA
HCC CONNECT is supported by Independent Educational Grant from Bayer

COR2ED develops and implements high quality Independent Medical Education programmes to help improve the health of patients globally.
Bodenackerstrasse 17
4103 Bottmingen
Disclaimer: The material and content contained in the website COR2EDEngage.com is for healthcare professionals only. Although every effort is made to ensure that the material within this website is accurate and timely, it is provided for informational and educational purposes only. The information provided is not intended as a substitute for medical professional help, advice, diagnosis or treatment and may not be applicable to every case or country.
© Copyright 2021 | All Rights Reserved 
Website design & maintenance by Zesty Digital
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram
We use cookies in order to give you the best possible experience on our website. By continuing to use this site, you agree to our use of cookies.